Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa + SOX + IP Nab-Paclitaxel in Advanced GC/GEJ Adenocarcinoma with Malignant Ascites
NCT07855757Active, not recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of retlirafusp alfa in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Ascites Objective Response Rate at 1 year. Started Jun 2026; status: active, not recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07855757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855757.